Free Registration: https://www.eventbrite.com/e/steven-f-udvar-hazy-center-tour-tickets-294901166327
- Hybrid Event: April 12th (Wednesday), 2023 at 6 pm EST
- Attend in person (Chemical and Nuclear Engineering Building, Room 2113A, 4418 Stadium Drive College Park, MD 20742-2111, please register at Eventbrite link above)
- Attend online (recieve Zoom link after Eventbrite Registration)
The AIChE National Capital Section (NCS) is excited to host Dr. Jeffrey Morton, head of the Life Sciences Group at Procopio, and Raph Y. Kim, Senior Associate at Procopio and they will be speaking at a special event at 6 pm EST on April 12th, Wednesday. They will be discussing how biotech startups are set up and grow successfully through corporate formation, IP strategy, IP transactions for licensing, mergers and acquisitions, financing and joint ventures. They will also discuss a career path as a patent practitioner for those who are interested.
- Event Agenda (Times in ET)
- 6:00 pm – Gathering at the Chemical and Nuclear Engineering Building
- 6:30 pm – Presentation by the Speaker
- 7:30 pm – Presentation Ends and Social Hours
About Procopio, Cory, Hargreaves & Savitch LLP and Life Sciences Practice Group:
Procopio is one of America's top AmLaw 200 corporate and litigation law firms, with nearly 200 attorneys in multiple offices throughout the United States. Procopio is on the U.S. News – Best Lawyers® Best Law Firms list for 2022.
Sixty Procopio attorneys representing 38 areas of law in four metropolitan areas were named by their peers as 2022 Best Lawyers in America® or Best Lawyers Rising Stars®. Procopio attorneys and practice groups are routinely named to various legal rankings lists, including Chambers and Partners®, Martindale-Hubbell®, and Super Lawyers®. Earlier this year, Procopio was certified by Diversity Lab as a Mansfield Plus firm for actively supporting and advancing attorneys of color, LGBTQ+ and lawyers with disabilities for leadership and governance roles, equity partner promotions, formal client pitch opportunities, and senior lateral positions. American Lawyer magazine ranks Procopio high among AmLaw 200 firms for attorney diversity, and the firm is recognized by Law360 as a Best Law Firm for Minority Attorneys.
Procopio’s Life Sciences attorneys bring decades of law firm and in-house counsel experience—from life-saving pharmaceuticals to breakthrough biotechnologies—offering a unique understanding of legal challenges and opportunities in rapidly evolving, multidisciplinary industries. For startups, emerging companies, and established multinational corporations, Procopio provides a wide range of legal services, including corporate formation, financing and venture capital, intellectual property counseling and litigation, licensing, real estate, mergers and acquisitions, and joint ventures.
Procopio counsels pharmaceutical and biotech companies, innovators in the biologics, genomic, diagnostic, e-health, digital health technologies, medical device designers and manufacturers, and other life sciences companies. Our life science experience includes gene therapy, tissue engineering, personalized cancer immunotherapy, TCRs, antibodies/peptibodies; antibody-drug conjugates (ADCs); protein therapeutics, cancer therapies, cellular immunotherapy, nucleic acids, as well as next-generation sequencing and modern genomics. Our chemistry technical expertise includes pharmaceuticals, industrial biotechnology, organic chemistry, and polymer chemistry, in areas as diverse as peptide pharmaceuticals, adhesives, drug delivery technology, and medical devices.
About Dr. Jeffrey Morton:
Jeff is the head of the Life Sciences Practice Group at Procopio, Cory, Hargreaves & Savitch LLP.
Jeff provides strategic intellectual property advice, including patent prosecution, and related transactional support for emerging and mature companies in a wide variety of industries, with a particular focus on life sciences and medical technologies. A PhD immunologist, he has extensive patent experience in technologies including genomics, immunology, and gene editing technologies, and advises on complex freedom-to-operate life sciences issues. Jeff also maintains an active trademark practice and provides cross-border legal advice with Canadian clients, being admitted in both the U.S. and Canada.
Jeff has been recognized by the World Intellectual Property Review as a U.S. Patent Leader and Trademark Leader and as an IAM Strategy 300 world-leading IP strategist.
Best Lawyers®, Biotechnology and Life Sciences, 2023
IAM Strategy 300 Global Leaders, 2022-2023
IAM Strategy 300: World-Leading IP Strategist, ranked in Legal-Technology Transfer, 2021-2022
IAM Patent 1000, 2022
California Trademark Leader, World Intellectual Property Review, 2022
Top Attorneys, San Diego Metro magazine, 2022
Leadership and Management Certificate, University of Pennsylvania Wharton School, 2019
JD, University of British Columbia Faculty of Law (Associate Editor, UBC Law Review), 2007
PhD (Immunology), Washington University in St. Louis School of Medicine, 2004
BSc (Biology and English), with distinction, University of Victoria Faculty of Science, 199
Co-presenter. “Is Your Life Sciences Patent Enabled?” webinar, March 14, 2023.
Author. “New USPTO Pilot Program Offers Opportunities for Cancer/Oncology Companies,” December 13, 2022.
Co-author. “Tacking in Headwinds: Integrating AI and Machine Learning in Life Sciences,” October 21, 2022.
Co-author. “What the PTAB’s CRISPR-Cas9 Decision for Broad Institute Means for Gene Editing Patent Landscape,” IP Watchdog, May 20, 2022.
Co-Author. “Keeping Valuable IP When a Key Employee Jumps to a Competitor,” Today’s General Counsel, January 24, 2022.
Co-Author. “Juno v. Kite Case Implications For Functionally Claimed Biological Compositions,” BioProcess Online, November 12, 2021.
Co-Author. “Collaboration Agreements: Critical Issues and Common Pitfalls,” BioProcess International, October 28, 2021.
Co-Author. “Presenting Working & Prophetic Examples in Patent Applications,” Co-Author, Bloomberg Law, September 8, 2021.
and many more.
About Raph Y. Kim:
Raph focuses on the strategic management of patent portfolio development and litigation support in a variety of life science other chemical technologies including pharmaceutical compounds, chemicals, and biomaterials. A chemical engineer, Raph has conducted advanced biological experiments for human stem cell research and tissue engineering, e.g., by designing and fabricating microfluidic chips and nano/micro-scale surface patterns, and has experience in molecular biology, genetic modification, biochemical assays, advanced imaging, and nano/micro technology for biological uses.
JD, American University Washington College of Law, Washington, DC, 2015
MS (Chemical & Biomolecular Engineering), Johns Hopkins University, Baltimore, MD, 2008
BS (Chemical & Biomolecular Engineering), Johns Hopkins University, Baltimore, MD, 2007
Co-author. “Pharma-Related Patent Enablement Reaches the Highest Court,” November 10, 2022.
Co-author. “Empowering American Innovation: APEX for Independent Inventors and the Public,” Berkeley Technology Law Journal, May 2016.
First co-author. “Spatial Control of Adult Stem Cell Fate Using Nanotopographic Cues,” Biomaterials, March 2014.
Co-author. “Simple Haptotactic Gradient Generation within a Triangular Microfluidic Channel,” Lab on a Chip, August 2010.
American Intellectual Property Law Organization (AIPLA), member
- Follow us for Events, updates, and networking at the NCS LinkedIn: https://www.linkedin.com/groups/8952605/
- Log in to post comments